Analysts Set Kalaris Therapeutics Inc. (NASDAQ:KLRS) PT at $14.00

Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS) have been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $14.00.

Several equities research analysts have weighed in on KLRS shares. Chardan Capital started coverage on Kalaris Therapeutics in a research note on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective on the stock. Wall Street Zen raised Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Finally, Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th.

Kalaris Therapeutics Price Performance

Shares of NASDAQ KLRS opened at $6.27 on Thursday. The business’s 50 day moving average is $8.55 and its two-hundred day moving average is $7.45. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $11.88. The stock has a market capitalization of $143.77 million, a P/E ratio of -1.49 and a beta of 0.18.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.12.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KLRS. RTW Investments LP bought a new position in shares of Kalaris Therapeutics during the fourth quarter valued at approximately $10,972,000. Paradigm Biocapital Advisors LP bought a new position in shares of Kalaris Therapeutics during the fourth quarter valued at approximately $5,908,000. Alyeska Investment Group L.P. bought a new position in shares of Kalaris Therapeutics during the fourth quarter valued at approximately $3,402,000. Ikarian Capital LLC bought a new position in shares of Kalaris Therapeutics during the fourth quarter valued at approximately $3,038,000. Finally, Woodline Partners LP bought a new position in shares of Kalaris Therapeutics during the third quarter valued at approximately $1,394,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.